EULAR 2025 highlights… EULAR 2026 Highlights – Metabolic & Crystal Arthropathies 22 Jul 2026 Treat-to-target continuation of urate-lowering therapy versus a urate-lowering therapy discontinuation attempt strategy in gout patients in remission (go test finale): a pragmatic open label randomised superiority trial Abstract format and…
EULAR 2025 highlights… EULAR 2025 Highlights – Metabolic and Crystal arthropathies 18 Jul 2025 Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial Abstract format and assignment number: Oral presentation OP0299…
EULAR 2024 Highlights… EULAR 2024 Highlights – Metabolic and Crystal arthropathies 21 Jul 202421 Jul 2024 Author: Juan C Sarmiento-Monroy Brikman et al. (OP0003) developed a machine learning-based prediction model for identifying hyperuricemic participants at risk of developing gout. The model demonstrated relatively good performance and…
ACR Highlights… ACR Convergence Highlights 2023 – Metabolic & Crystal arthropathies 9 Dec 20239 Dec 2023 Author: Dálifer Freites Núñez Tedeschi et al. (0234) performed a secondary analysis using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial. Among 6183 participants in this analysis,…